EGFR and non-small cell lung carcinoma: Interestingly, Erlotinib-resistant EGFR mutation in NSCLC enhanced NF-κB activity, while NF-κB inhibitors rescued the erlotinib sensitivity in resistant cells (Bivona et al., 2011).